不同质子泵抑制剂联合替戈拉生对胃溃疡的治疗效果评价

Objective To evaluate the therapeutic efficacy of tegoprazan in combination with different proton pump inhibitors(eg, rabeprazole or omeprazole) for gastric ulcer, aiming to provide a reference for clinical management. Methods A total of 90 patients with gastric ulcers admitted from June 2023 to June 2025 were selected and randomly divided into a control group(45 cases) and an observation group(45 cases) using a random number table method. All patients received standardized quadruple therapy with bismuth agents, all were treated with tegoprazan to enhance acid inhibition and efficacy. The control group was treated with omeprazole as the proton pump inhibitors(PPI), while the observation group received rabeprazole as the PPI. After 8 weeks of treatment, clinical efficacy, symptom relief duration, serum indicators, histopathological scores of gastric mucosa, ulcer area, and adverse reactions were compared between the two groups. Results Compared with the control group, the observation group demonstrated a significantly higher overall response rate(95.56% vs. 82.22%, P<0.05) and a shorter time to symptom relief(P<0.05). Post-treatment serum analysis revealed that levels of transforming growth factor-β1(TGF-β1) and tumor necrosis factor-α(TNF-α) were lower, while α-defensin was higher in the observation group relative to the control group(P<0.05). Furthermore, both the gastric mucosal histopathological score and the ulcer area were significantly reduced in the observation group compared to the control(P<0.05). Although the incidence of adverse events was numerically lower in the observation group(8.89%) than in the control group(22.22%), this difference did not reach statistical significance(P>0.05). Conclusion The combination of rabeprazole and tiglazuridine demonstrates superior therapeutic effects in treating gastric ulcers compared to omeprazole and tiglazuridine, with faster symptom relief, improved inflammatory response, and ulcer healing, along with higher safety.